Literature DB >> 26447618

[Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai].

Xunxun Cao1, Yueqiu Gao, Wenhong Zhang, Ping Xu, Qingchun Fu, Chengwei Chen, Chengzhong Li, Changqing Yang, Guangbin Ma, Ying Qu, Mingyi Xu, Lungen Lu.   

Abstract

OBJECTIVE: To investigate the epidemiological status of cholestasis in first-hospitalized patients with chronic liver disease in Shanghai, and to provide a scientific basis for developing prevention and treatment measures.
METHODS: From April 2005 to September 2014, 5,146 first-hospitalized patients in Shanghai with a diagnosis of chronic liver disease were enrolled in this study. Clinical data of the 4,660 patients who fit the study criteria for participation were collected for retrospective analysis.Diagnosis of cholestasis was made according to serum alkaline phosphatase (ALP) levels higher than 1.5 times the upper limit normal (ULN) and gamma-glutamyltransferase (GGT) levels higher than 3 times the ULN. The incidence rate of cholestasis was assessed for relation to age, sex, etiology, and type of liver disease, and statistically compared to the general clinical data and specific biochemical indicators with potential sex-related differences. T-test and chi-square test were performed for the statistical analyses.
RESULTS: Of the 4,660 study participants, 10.26% had cholestasis; the prevalence of cholestasis increased with increasing age in male patients. The distribution of the cholestasis incidence according to the type of chronic liver disease was: 75.00%, primary sclerosing cholangitis; 42.86%, primary biliary cirrhosis; 35.97%, hepatic tumor; 30.77%, autoimmune hepatitis; 28.31%, drug-induced liver disease; 16.46%, alcoholic hepatitis; 13.98%, cryptogenic cirrhosis; 12.99%, schistosomal cirrhosis; 7.53%, alcoholic cirrhosis; 7.32%, mixed cirrhosis; 5.94%, viral liver cirrhosis; 2.70%, nonalcoholic fatty liver disease. There was no significant difference in the prevalence of cholestasis between the two sexes. In the patients with cholestasis, the levels of GGT and total bilirubin were significantly different between the two sexes.
CONCLUSION: The incidence rate of cholestasis in first-hospitalized patients with chronic liver disease was 10.26%, and the rate increased with increased age. Patients with primary sclerosing cholangitis or primary biliary cirrhosis had higher incidence rates of cholestasis. Incidence rates of cholestasis of the various chronic liver diseases were not related to sex.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26447618     DOI: 10.3760/cma.j.issn.1007-3418.2015.08.003

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  5 in total

1.  Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes.

Authors:  Andressa Franca; Antonio Carlos Melo Lima Filho; Mateus T Guerra; Jittima Weerachayaphorn; Marcone Loiola Dos Santos; Basile Njei; Marie Robert; Cristiano Xavier Lima; Paula Vieira Teixeira Vidigal; Jesus M Banales; Meenakshisundaram Ananthanarayanam; M Fatima Leite; Michael H Nathanson
Journal:  Hepatology       Date:  2018-12-31       Impact factor: 17.425

2.  Melatonin ameliorates ANIT‑induced cholestasis by activating Nrf2 through a PI3K/Akt‑dependent pathway in rats.

Authors:  Yunzhou Li; Han Yu; Zongying Xu; Shaohua Shi; Dingnan Wang; Xinghua Shi; Yuchen Wang; Baihui Zeng; Huifang Deng; Xiulan Deng; Xianggen Zhong
Journal:  Mol Med Rep       Date:  2018-12-12       Impact factor: 2.952

3.  Predicting Target Genes of San-Huang-Chai-Zhu Formula in Treating ANIT-Induced Acute Intrahepatic Cholestasis Rat Model via Bioinformatics Analysis Combined with Experimental Validation.

Authors:  Jiaming Yao; Junbin Yan; Jinting Wu; Jianshun Yu; Beihui He; Xi Chen; Zhiyun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-01       Impact factor: 2.629

4.  Guidelines for the Management of Cholestatic Liver Diseases (2021).

Authors:  Lungen Lu
Journal:  J Clin Transl Hepatol       Date:  2022-04-29

5.  Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics, multivariate data and pathway analyses.

Authors:  Han Yu; Yunzhou Li; Zongying Xu; Dingnan Wang; Shaohua Shi; Huifang Deng; Baihui Zeng; Zhili Zheng; Lili Sun; Xiulan Deng; Xianggen Zhong
Journal:  Int J Mol Med       Date:  2018-09-05       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.